Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders

Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders

Assignment: All study subjects will undergo the same interventions.
Delivery of Interventions:

The subject will undergo a review of their medical history, physical exam, and screening laboratories.
A pelvic ultrasound will be performed to assess baseline follicular size.
A pump will be placed to administer pulsatile SC kisspeptin for two weeks.
During the course of kisspeptin administration, subjects will 1)Undergo q10 min blood sampling (approximately 4 sessions, 2 hours each) 2) Undergo pelvic ultrasounds (approximately 4 sessions)
Optional q10 min sampling up to 10 hours may take place before and after the course of kisspeptin

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

December 2, 2022Comments OffClinicalTrials.gov | Endocrinology Clinical Trials | Endocrinology Studies | US National Library of Medicine
Comments